480 related articles for article (PubMed ID: 27382012)
1. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
2. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
5. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
6. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
8. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
9. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Jadhavar PS; Ramachandran SA; Riquelme E; Gupta A; Quinn KP; Shivakumar D; Ray S; Zende D; Nayak AK; Miglani SK; Sathe BD; Raja M; Farias O; Alfaro I; Belmar S; Guerrero J; Bernales S; Chakravarty S; Hung DT; Lindquist JN; Rai R
Bioorg Med Chem Lett; 2016 Nov; 26(21):5222-5228. PubMed ID: 27717544
[TBL] [Abstract][Full Text] [Related]
10. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
13. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
[TBL] [Abstract][Full Text] [Related]
14. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
16. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
17. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
19. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
